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See Article, pages 41–48Barriers exist to protect. The ﬁrst images of World War II show
the invaders breaking a barrier at the border of Poland, signifying
the end of a peaceful world and the beginning of chaos. . . This is
analogous to viral resistance to antiviral drugs. The invader is the
drug-resistant virus; this virus preexists as poorly ﬁt, minority
viral populations. The ‘‘barrier to resistance’’ of a drug or a drug
combination prevents their outgrowth in the presence of the
drug(s), thus preventing virological breakthrough, disease pro-
gression, and eventually severe complications. If the barrier to
resistance is high enough, resistant viral variants are not selected
and do not grow; if it is not, they rapidly ﬁll in the replication
space and become the dominant (or exclusive) viral population
associated with high-level replication.
The main components of the barrier to resistance in vivo are:
(i) the ‘‘genetic barrier to resistance’’, deﬁned as the number of
amino acid substitutions needed for a viral variant to acquire full
resistance to the drug in question. If a single substitution is suf-
ﬁcient to confer high-level resistance, then the drug is considered
to have a low genetic barrier to resistance, while the need for
three or more substitutions represents a high genetic barrier;
(ii) the ‘‘in vivo ﬁtness’’ of the resistant viral variant population,
deﬁned as its ability to survive and grow in the replicative envi-
ronment; (iii) drug exposure, deﬁned as the drug concentration
achieved in vivo relative to the 50% and 90% inhibitory concentra-
tions (IC) and efﬁcient concentrations (EC) [1].
A number of direct acting antiviral (DAA) drugs are in devel-
opment for the treatment of chronic hepatitis C virus (HCV) infec-
tion. Two NS3/4A protease inhibitors, telaprevir and boceprevir,
have been recently approved in combination with pegylated
interferon (IFN)-a and ribavirin for the treatment of genotype 1
chronic hepatitis C [2–5]. Other DAAs are at various stages of pre-
clinical to late clinical development. They can be schematically
classiﬁed into two groups, according to their barrier to resistance.
Drugs with a low barrier to resistance include ﬁrst-generation
NS3/4A protease inhibitors (e.g. telaprevir and boceprevir and
numerous other molecules in development), NS5A inhibitors,
and non-nucleoside inhibitors (NNI) of HCV RNA-dependent
RNA polymerase (RdRp) [6]. Their administration as monothera-
pies has been reported to be associated with early virologicalJournal of Hepatology 20
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of ﬁt resistant viral populations carrying one or several substitu-
tions that confer resistance to the drug [7–9]. Drugs with a high
barrier to resistance include nucleoside/nucleotide analogue
inhibitors of HCV RdRp, cyclophylin inhibitors (drugs that target
a host cell protein involved in viral replication), and potential sec-
ond-generation NS3/4A protease inhibitors. They can be adminis-
tered alone for weeks without any virological breakthrough due
to resistance in the majority of cases [10,11].
Prevention of resistance, particularly when drugs with a low
barrier to resistance are used, is based on the combination of sev-
eral molecules that are potent and have no cross-resistance. No
cross-resistance means that each member of the combination is
fully active on viruses that are resistant to the others. This concept
was the basis for combining NS3/4A protease inhibitors (or other
DAAs with a low barrier to resistance) with pegylated IFN-a and
ribavirin. Unfortunately, in patients who do not respond ade-
quately to IFN-a and ribavirin, treatment fails and as a result
DAA-resistant variant populations grow [1]. In order to cure infec-
tion without selecting for resistance, it is also possible to combine
potent DAAs without cross-resistance, with the double goal of
achieving better antiviral efﬁcacy and substantially increasing
the barrier to resistance. Attempts with combinations of drugs
with low barriers to resistance, such as an NS3/4A protease inhib-
itor with an NS5A inhibitor, or an NS3/4A protease inhibitor with
an NNI, have been disappointing [12,13]. Although cure was
achieved in a few patients receiving the former combination
[14], the rates of failure due to selection of viral variants bearing
substitutions at both drug target sites were frequent in these
studies, suggesting that the barrier to resistance of a combination
of two HCV drugs with low barriers to resistance is not dramati-
cally greater than that of each drug alone.
There are four distinct groups of NNI inhibitors of HCV RdRp
in development. Each targets a different allosteric site at the sur-
face of the enzyme, and they have been reported to have different
resistance proﬁles in vitro, without cross-resistance. Thus,
although targeting the same viral enzyme, NNIs from different
classes could theoretically be combined together. In this issue
of the Journal of Hepatology, Delang et al. report their assessment
of the antiviral potencies and resistance selection proﬁles of
members of three of the four NNI groups [15]. These compounds
were tested alone and in double or triple combination in repli-
con-harboring Huh7 cell lines, the usual model for this type of12 vol. 56 j 11–13
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experiments. The authors conﬁrmed the low barrier to resistance
of each NNI alone and the lack of cross-resistance between them.
They also showed that these drugs have additive antiviral effects
in vitro.
When a stepwise, long-term procedure was used, the authors
were able to select variants resistant to each pair-wise combina-
tion, which carried amino acid substitutions conferring high-level
resistance to both tested NNIs on the same strain. Triple resistant
replicons were also generated, starting from a replicon that was
already resistant to two NNIs and was subsequently exposed to
the third one. The triple-resistant replicons harbored substitu-
tions conferring resistance to the three drugs tested. It was also
cross-resistant with the fourth class of NNIs, not used in the
experiments [15]. Whether such triple resistant variants natu-
rally preexist in infected patients remains unknown. Short-term
replication models, such as replicons in Huh7 cell lines, could
underestimate the extent of HCV variability encountered in
patients who have been infected for decades. Indeed, it has been
recently suggested, based on mathematical modeling, that in
HCV-infected patients, all possible single and double mutants
are generated multiple times each day, all viable single and dou-
ble mutants that confer drug resistance preexist and may com-
pete with the wild-type virus during therapy, and triple
mutants can be selected by sequential mutations when single
or double mutants replicate [16]. It is therefore highly likely that
HCV variants that are resistant to three drugs preexist at baseline
in a substantial proportion of patients, or that they can be gener-
ated through replication of double-resistant viruses.
Resistance to DAAs is often feared as the main cause of treat-
ment failure with new HCV therapies. This is not the case with
the triple combination of a DAA with pegylated IFN-a and ribavi-
rin, during which treatment failure results of an inadequate
response to IFN-a that favors the outgrowth of resistant viral
variants selected by the DAA [1–5]. In contrast, control of resis-
tance will be key during the era of all-oral, IFN-free regimens.
Indeed, antiviral potency and a high barrier to resistance are
required to ensure that inhibition of HCV production is sustained
for a sufﬁcient amount of time in order for every infected cell to
clear the remaining viruses. If any viral population is not con-
trolled by the drug combination, it replicates, is produced, infects
new cells and leads to treatment failure. Intuitively, the best way
to prevent such failure is to include at least one drug with a high
barrier to resistance, such as a nucleoside/nucleotide analogue or
a cyclophylin inhibitor, in any combination of HCV DAAs. How-
ever, these drugs have not yet reached the market and the results
of long-term combination studies including one or two nucleo-
side/nucleotide analogue(s) are awaited.
What will be the role of NNIs in this context? Recent results
with the two most advanced in development NNIs, tegobuvir
and ﬁlibuvir, have been disappointing: no difference was
observed between the triple combination of different doses of
the NNI with pegylated IFN-a and ribavirin vs. pegylated IFN-a
and ribavirin alone [17,18]. Nevertheless, this failure appears to
be principally related to the lack of antiviral potency of these
compounds rather than to their barrier to resistance, which is
not fundamentally different from that of telaprevir or boceprevir.
It is therefore possible that more potent NNIs could prove to be
useful in combination with pegylated IFN-a and ribavirin.
What the study by Delang et al. teaches us is that combina-
tions of NNIs are unlikely to be helpful, even if the molecules
belong to different classes, have different target sites and no12 Journal of Hepatology 20cross-resistance. In vitro results in the replicon system have pro-
ven to be accurate in predicting resistance in vivo; thus, single,
double, and triple-resistant variants are likely to be selected early
by NNI combinations in infected patients. How will we use NNIs
in IFN-free regimens in the future? Ideally, in combinations
including at least one drug with a high barrier to resistance
(e.g. a nucleoside/nucleotide analogue, a cyclophylin inhibitor,
or a second-generation NS3/4A protease inhibitor with an
improved resistance proﬁle compared to ﬁrst-generation ones).
Nevertheless, if these drugs are potent enough, they should, at
least theoretically, be able to block virus production without
resistance emergence for long enough for the virus to be cleared
by host cells without the need for other drugs. If this is the case,
drugs with a narrow genotype coverage and a low barrier to
resistance, such as NNIs, may not be absolutely required in the
HCV drug armamentarium. This question will be solved by ongo-
ing and future clinical trials.
Overall, trial designers and clinicians should remember that, if
resistance is not a major threat in patients treated with the triple
combination of a DAA with pegylated IFN-a and ribavirin, since
the ﬁnal outcome depends mainly on the IFN response, its pre-
vention will be key in the design of all-oral treatment strategies
based on DAA combinations. Only combinations with a high
enough barrier to resistance should be envisaged, as they are
the only ones that can ensure sustained inhibition of viral pro-
duction for the time needed for host cells to get rid of the virus.
As in any war, the ﬁnal victory depends on the allies you chose.
Our mission is now to ﬁnd the best alliance to keep the invaders
out. This is the price to pay for a peaceful world, i.e. a world with-
out hepatitis C.
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